Roche opens access to pathology imaging tools to improve patient care

NEXT STORY
Pulmocide’s lead drug candidate opelconazole (PC945) granted Orphan Drug, Fast Track and Qualified Infectious Disease Product Designations by US FDA
PREV STORY
Avalo Therapeutics, Inc. Announces Pricing of $27.5 Million Public Offering of Common Stock
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Novartis announces EU approval of Mayzent® (siponimod) for adult patients with secondary progressive multiple sclerosis (SPMS) with active disease

author_avatar
NASDAQ Market News

Aquestive Therapeutics Receives Notification from FDA that It Will Not Be Ready to Take Action by December 23, 2021 for the Company’s NDA for Libervant™ (diazepam) Buccal Film

author_avatar
NASDAQ Market News

Biomea Fusion Reports Second Quarter 2021 Financial Results and Business Highlights

author_avatar
NASDAQ Market News